Cutler Group LP Ascendis Pharma A/S Transaction History
Cutler Group LP
- $307 Million
- Q1 2024
A detailed history of Cutler Group LP transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Cutler Group LP holds 440 shares of ASND stock, worth $63,395. This represents 0.02% of its overall portfolio holdings.
Number of Shares
440Holding current value
$63,395% of portfolio
0.02%Shares
13 transactions
Others Institutions Holding ASND
# of Institutions
236Shares Held
59.6MCall Options Held
108KPut Options Held
234K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.46 Billion22.55% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.53MShares$797 Million3.52% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.1MShares$735 Million10.24% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.45MShares$641 Million0.98% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$631 Million0.32% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $8.04B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...